His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.
from WebMD Health https://ift.tt/DqZr5sj
His tumor had a specific genetic makeup known as mismatch repair-deficient, present in 5% to 10% of all rectal cancer patients, meaning he might qualify for a cutting-edge immunotherapy.
0 comments:
Post a Comment